Strategic Management Board
The Strategic Management Board's role is oversight and direction of the programme. Membership of the board will consist of stakeholders and advisors who will help guide the programme to a successful conclusion, delivering the strategic aims of the programme as set out in the proposal and delivering impact.
We are currently looking for two members of the public to join our Strategic Management Board!
Professor Andrew Mount, FRSC - CHAIR
Professor Andy Mount is Professor of Physical Electrochemistry and Dean of Research in the College of Science & Engineering (CSE) at the University of Edinburgh.
His research interests include fundamental and applied electrochemistry, sensing and analysis and the development and application of healthcare and low carbon clean energy technologies; he has played a leading role in over £40million of major multidisciplinary collaborations across Scotland, the UK and Europe. As Director of Research he played a key role in the establishment of EaStCHEM, the joint chemistry research School of the Universities of Edinburgh and St Andrews, and he coordinated the highly successful CSE REF2014 submissions as Dean of REF. As Dean of Research he is now leading CSE research and impact strategy and development.
He is a Fellow of the Royal Society of Chemistry (RSC), Chair of the RSC Faraday Standing Committee on Conferences and a member of RSC Faraday Division Council. He is also member of the Science Advisory Committee of the Scottish Universities Environmental Research Centre, is external examiner for Chemistry degrees at the University of Warwick and was previously external examiner for Chemistry at the University of Bath.
Mary is Director for Scotland at Breast Cancer Now, the UK’s largest breast cancer charity and one with a focus on cancer research. Mary has headed up the charity in Scotland since Oct 2015. She is also the current Chair of the Scottish Cancer Coalition which represents 27 different cancer charities in Scotland and acts to promote dialogue and engagement between policy-makers and charities.
Mary moved to this role following 12 years in the NHS in Scotland in research, strategy and latterly a strategic delivery focussed role. Mary started her career as a social science researcher in the University of Edinburgh.
Professor David Cameron
Prof. Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year. Prof. Cameron is a member of several professional societies including the American Society of Clinical Oncology & the European Society for Medical Oncology. He has also been a member of the EORTC task force on the use of growth factors in chemotherapy for solid tumours and lymphoma and a past chairman of the EORTC New Agent Committee. He is a past member of the Scottish medicines Consortium project and the Scottish short-life working group on the use of unlicensed cancer medicines.
He is active in a number of clinical trials in breast cancer. He is a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials (AZURE, OPTION, TACT, TANGO, MAMMO50, ARTEMIS, PERSEPHONE, ROSCO and TEAM) as well as the BIG APHINITY, ALTTO/NEO_ALTTO, BRAVO and AURORA studies. He is chief investigator on the recently reported UK trial adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer. He jointly chairs the ENCHANT phase II study of an HSP90i in breast cancer.
Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and at the end of 2009 took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian. In this role he is the clinical director of the Edinburgh Cancer Research Centre (including the CRUK funded Edinburgh Cancer Centre and the joint Edinburgh-Dundee Experimental Cancer Medicine Centre), and has responsibility for oversight and strategy of clinical and translational research in cancer in Edinburgh. He continues his major clinical interest in breast cancer with an on-going clinical and translational research programme. He is a present and past member of several cancer research funding committees including INCA PHRC, PEAR, Cancer Research UK Science committee and from time to time NIHR funding bodies. He was recently appointed as the Chief Scientist’s Office Clinical Cancer Research Champion in Scotland to act as a focal point for current and future clinical research in cancer in Scotland.
As CEO Dave determines the strategic direction, optimises and implements the business operational plans required to establish DHI as a leader in digital health and care.
Over the last 25 years, Dave has held several senior director level roles, culminating in appointments as the Interim CEO of three of Scotland’s Innovation Centres, where the objective is to link an industrial or social need with an academic capability and facilitate the creation of projects which eventually bring measurable financial, social or health (including wellbeing) benefit to Scotland.
Dave’s role has been to determine the strategic direction, optimise and implement the business operational plans required to establish new businesses from scratch or during a renewal in direction and funding.
Having successfully done this for CENSIS and The Datalab Innovation Centres, which required leadership in difficult circumstances and the ability to build multidisciplinary teams virtually from scratch, Dave then organised formal handovers of these, by then, fully functioning businesses, to the incoming permanent CEO’s.
Dave has recently taken on the role as the Interim CEO of the Digital Health & Care Institute. The Innovation Centre is addressing the challenging problems of supporting our health and care institutions to deliver more efficient and importantly effective services to the Scottish community and beyond. A principle means to achieve this being the innovative application of digital technology.
Prior to his Innovation Centre appointments, Dave was the Technical and Product Management Director of Thales Optronics. Thales Optronics is part of a multinational equipment and systems supplier with a UK turnover of circa £1.6bn and 8000 staff delivering defence, security, transport and aerospace solutions. In this role he was responsible for product management across six sites, with a £300m turnover and 1600 staff.
Gillian has over 22 years’ experience working in the IT sector. Gillian is responsible for delivering the strategic vision set out by The Data Lab Board, the aim of which is to create over 250 new jobs and to generate more than £100 million to Scotland’s economy.
Prior to this Gillian held a range of Senior Leadership roles at IBM UK including Leader for Software Business in Scotland, Systems and Technology Sales Leader and Territory Leader for General Business Scotland.
Gillian is on the Board of Tech Partnership Scotland and is also a Board member of the Glasgow Chamber of Commerce. Gillian has a degree in Computing Science from Glasgow University and is married with a daughter.
Dr Diane Harbison
Diane brings more than 20 years knowledge and experience in life sciences to this role, gained from senior roles in industry, academia and in SMEs, including the European Bioinformatics Institute and Pfizer, where she was head of e-biology. She moved into business development at Pfizer, where she was responsible for negotiating licenses and collaborations to enable access to novel technologies and assets up to the pre-proof of concept stage. She was recruited to establish the business development team at Edinburgh BioQuarter. Under her leadership, the BioQuarter business development team successfully established strategic alliances with many of the top 10 pharmaceutical companies. Subsequently as Managing Director of BioCity Scotland, she was instrumental in increasing tenant occupancy and achieving Enterprise Area Status for the site.
Professor Aileen Keel, CBE
Aileen Keel is seconded from Scottish Government to the Usher Institute of Population Health Sciences and Informatics at the University of Edinburgh to lead the IHDP.
Aileen joined the Scottish Office (as was) as a Senior Medical Officer in the Department of Health in 1992.
She was Deputy Chief Medical Officer in Scottish Government Health and Social Care Directorates from 1999 to 2014. Between April 2014 and May 2015 she was acting Chief Medical Officer.
She is Chair of the Scottish Cancer Task Force, Co-chair of COMQI (Clinical Outcomes and Measures for Quality Improvement), and honorary consultant in haematology at Edinburgh Royal Infirmary and has an Honorary Chair at the University of Edinburgh.
Professor Alex McMahon
Alex started his career as a NHS student nurse in 1983 and is a registered mental health and general nurse and has held senior clinical, policy and strategic roles across the public and private sectors as well as within Government.
He took up the post as Head of Policy at the Royal College of Nursing before leaving that post in 2002. Alex then moved to AstraZeneca, a global pharmaceutical company, as their Head of Government Affairs for Scotland and Ireland. This position led Alex to go onto work for the Scottish Government for five and a half years before joining NHS Lothian in September 2008.
His current post is Director for nursing, midwifery and AHPs as well as the executive director responsible for REAS (Royal Edinburgh and Associated Services) and prison healthcare, strategic planning and clinical education and training.
In addition to his work with NHS Lothian, Alex is also an honorary chair of the University of Stirling.
Dr Hester Ward
Dr. Hester Ward is a Consultant in Public Health Medicine at Information Services Division (ISD) & Health Protection Scotland (HPS), NHS National Services Scotland, and an Honorary Reader at the University of Edinburgh.
Hester provides public health leadership and expertise in the following areas focusing on information and intelligence: primary care, health and social care integration, unscheduled care and dementia, specifically Creutzfeldt-Jakob disease (CJD). Previously, she spent 10 years at the National CJD Research & Surveillance Unit undertaking epidemiological research into risk factors for CJD. She has been a member of an NHS Ethics’ Committee for over 10 years.
She is interested in facilitating the use of data, governed in a secure and proportionate way, for research and innovation to benefit the health of the population of Scotland.